Federal biotech lab gets $55–$85M annual boost to set industry standards
H.R. 8981 — SCALE Biology Act · Filed by April McClain Delaney (D-MD) · 5 cosponsors · Introduced May 21, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a new federal research program at NIST (the National Institute of Standards and Technology) focused on engineering biology, biomanufacturing, and biotechnology. The program will develop measurement standards, technical guidelines, and best practices to help U.S. industry innovate in biological manufacturing and compete globally, while also addressing biosafety and biosecurity concerns. It authorizes $55–$85 million annually through 2030 for research, user facilities, workforce training, and coordination with industry and universities.
Why we flagged it
The bill's core mechanism is establishing a federal research program at NIST to develop voluntary technical standards and measurement science for emerging biotechnology sectors. It is fundamentally a public-sector capacity-building and coordination instrument, not a subsidy, deregulation, or private carve-out.
What the text implies
- The bill's emphasis on 'voluntary, consensus-based' standards may create a de facto private-sector role in defining what counts as safe or secure biotech practice, potentially limiting future regulatory authority if industry standards become entrenched.
- The 'engineering biology foundry' language suggests NIST will support private-sector manufacturing infrastructure, blurring the line between public research and private commercialization support.
The full analysis lists 5 implications of this text.
Who stands to gain
biotechnology companies and startups; biomanufacturing firms; institutions of higher education (research funding)